GLPwatch
Liraglutide
Approved · GLP-1 receptor agonist
Last updated 2026-09-22Liraglutide is a drug that mimics a natural hormone called GLP-1, which helps control blood sugar and appetite. It is sold under the brand names Saxenda and Victoza, which are approved to treat type 2 diabetes, obesity, and to reduce cardiovascular risk.
AI summary of the sources below.
| Mechanism | GLP-1 receptor agonist Mimics GLP-1, a gut hormone that raises insulin, lowers blood sugar, and reduces appetite. |
|---|---|
| Status | Approved |
| Branded products | saxenda, victoza |
| Manufacturer(s) | novo-nordisk |
How Liraglutide connects
- Products SaxendaVictozaXultophy
- Treats ObesityType 2 diabetesCardiovascular risk reduction
- Maker Novo Nordisk
- Trials 328 trials
- Research 2,307 papers
Trials (328)
- Research Study Comparing a New Medicine Semaglutide to Liraglutide in People With Type 2 Diabetes
- Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial Disease
- Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)
- Influence of Liraglutide, a GLP-1 Receptor Agonist, on Brown Adipose Tissue (BAT) Activity in Humans
- The Effect of a Liraglutide on IVF in Obese PCOS
- Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus
- Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers
- Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
- Liraglutide to Improve corONary Haemodynamics During Exercise streSS
- Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes
- Liraglutide and Cardio-Metabolic Risk Markers
- Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
- Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes
- Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
- Tirzepatide vs Liraglutide in Bone
- Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility
- Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent
- Liraglutide Versus Insulin Mono-therapy in the Closed Loop Setting
- A 104 Week Clinical Trial Comparing Long Term Glycaemic Control of Insulin Degludec/Liraglutide (IDegLira) Versus Insulin Glargine Therapy in Subjects With Type 2 Diabetes Mellitus
- Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
- A Trial Comparing the Efficacy and Safety of Liraglutide 1.8 mg/Day to Liraglutide 0.9 mg/Day in Japanese Subjects With Type 2 Diabetes Mellitus.
- Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function
- Liraglutide in Adolescents With Type 1 Diabetes
- Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus
- A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes
Top research (2307)
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
- The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study.
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.
- A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide.
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial.
- Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial.
- Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
- Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study.
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial.
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE<sup>-/-</sup> and LDLr<sup>-/-</sup> Mice by a Mechanism That Includes Inflammatory Pathways.
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.